01. Product portfolioProTransStudy TeamCellaviva
02. About NextCellBusiness ConceptVision, mission, strategyHistory
OrganisationCompany Structure
03. InvestorsRights Issue 2024NextCell as an investmentFinancial CalendarFinancial ReportsCorporate GovernanceCertified AdviserThe ShareArchive
04. NewsQ&A with CEOPress ReleasesCompany Presentations
05. ContactContact InformationSubscribe
English
/
Svenska

NextCell Pharma publishes Interim Report 2 2021/2022

April 28, 2022
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period September 1, 2021 – February 28, 2022 The report is available on the company’s website:https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.
Second quarter (2021-12-01 until 2022-02-28)

● Operating income amounted to 1 840 (1 008) TSEK.
● Operating result amounted to -10 212 (-8 149) TSEK.
● Earnings per share* amounted to -0,30 (-0,27) SEK.
● Cash and bank amounted to 118 170 (148 936) TSEK.
● Solidity** amounted to 94,3 (96,8) %.

First half-year (2021-09-01 till 2022-02-28)

● Operating income amounted to 3 187 (2 141) TSEK.
● Operating result amounted to -16 906 (-13 678) TSEK.
● Earnings per share* amounted to -0,22 (-0,51) SEK.
Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the second quarter 2021/2022: 34,379,523 (29,717,519) shares. Average number of shares for the first half year 2021/2022: 34,379,523 (26,540,470) shares. Number of shares in NextCell as of February 28, 2022: 34,379,523 (33,712,857) shares. **Solidity: Own capital's share of the sheet total

‍

Significant events in the second quarter

● NextCell announced in December that it has entered into a cooperation agreement with T.A.D.1, a non-profit association whose purpose is to increase knowledge in society about type 1 diabetes and run projects in support of everyone living with and around T1D. Together we want to spread hope fortype 1 diabetes research and make NextCell's clinical trials visible.
● NextCell announced in January that the company's CEO, Mathias Svahn, had been invited to give a presentation about the company's journey in cell therapy at the Advanced Therapy Week in Miami, USA at the end of January.
● NextCell announced in early February that the company had increased its involvement in FamiCordTx, a joint venture in cell and gene therapy, in a new share issue by approximately 160 kEUR.
● NextCell announced in mid-February that a Pediatric Diabetes Study is underway and that the company is contributing ProTrans and placebo.
● NextCell announced at the end of February that the Canadian probation for ProTrans in COVID-19 will be expanded to a multicenter study
● NextCell announced at the end of October that the clinical trial ProTrans19+SE can begin recruiting patients in the mean dose group. Three patients treated with a low dose of ProTrans have been clinically evaluated and the data have been reviewed by the Safety Committee, which now allows continued medium-dose treatment of ProTrans for severe pneumonia caused by COVID-19.

Significant events after the reporting period

● NextCell announced in early April that the stem cell bank Cellaviva has disclosed stem cells from umbilical cord blood to Rigshospitalet, Denmark's premier hospital. A sibling of the child whose umbilical cord blood was saved in cellovia's biobank, suffers from a serious blood disorderto be treated with stem cells at the Hematology Department at Rigshospitalet.
● NextCell announced in early April that all three children in the age group 12-18 years have been treated with ProTrans. Professor Per-Ola Carlsson and the study team are now moving forward with younger patients, three children in the age group 7-11 years.

This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 28-04-2022 08:00 CET.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: 08-735 5595
E-mail: info@nextcellpharma.com

Websites:
www.nextcellpharma.com
www.cellaviva.se
www.cellaviva.dk
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
Instagram: https://www.instagram.com/cellaviva/

About NextCell Pharma AB

NextCell is a phase II cell therapy company with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to take ProTrans to market approval via a Phase III study. ProTrans is in addition to diabetes, used in two clinical trials for Covid-19, in Örebro and Montreal (Canada). The company is in the processes of establishing its own GMP facility for production of ProTrans. The GMP facility is expected to be ready for production of smaller quantities of ProTrans in 2023. NextCell furthermore owns 8,5% in FamicordTX, a CAR-T start-up in oncology and 100 % of Cellaviva, Scandinavia's largest stem cell bank for family saving stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO)

Download attachmentRead full press release on Cision (external link)
2019-05-17
Six out of nine patients in the phase-II part of the ProTrans-1 study have completed treatment
NextCell Pharma AB (NextCell) announces that six out of the nine patients included in ProTrans-1, the trial with the drug candidate ProTrans, now have completed treatment and left the study. Earlier this week, the last of the three patients in the so-called medium-dose-cohort visited for their 12-month follow-up, the final part of the trial, which means that all three now have completed their part of the trial. In early March, the three patients in the low-dose cohort had already completed the trial. This means that six out of nine patients in the phase II part have now successfully
NextCell Pharma AB (NextCell) announces that six out of the nine patients included in ProTrans-1, the trial with the drug candidate ProTrans, now have completed treatment and left the study. Earlier this week, the last of the three patients in the so-called medium-dose-cohort visited for their 12...
Read moreRead more
2019-05-15
NextCell Pharma invited speaker at the World Advanced Therapies & Regenerative Medicine Congress
NextCell Pharma AB ("NextCell") and Cellaviva have been invited to attend and speak at the 14th annual World Advanced Therapies & Regenerative Medicine Congress, which is held at the Business Design Centre, London 15 - 17 May. On 16 May, CEO Dr. Mathias Svahn will be chairing the Roundtable Discussion Session regarding hospital exemption procedures. For the duration of the conference NextCell/Cellaviva delegates will be participating in workshops, attending lectures and engaging in a variety of networking activities.  The World Advanced Therapies & Regenerative Medicine Congress is an
NextCell Pharma AB ("NextCell") and Cellaviva have been invited to attend and speak at the 14th annual World Advanced Therapies & Regenerative Medicine Congress, which is held at the Business Design Centre, London 15 - 17 May. On 16 May, CEO Dr. Mathias Svahn will be chairing the Roundtable Discu...
Read moreRead more
2019-05-09
ProTrans-Repeat, an approved clinical trial for repeated treatment of patients with diabetes
The Medical Products Agency has granted NextCell Pharma AB ("NextCell") permission to conduct the new study, ProTrans-Repeat. The study is a continuation of ProTrans-1 where patients with type-1 diabetes who participated in the dose escalation part will be asked to participate in ProTrans-Repeat. The purpose is to investigate whether repeated treatment is safe and gives increased effect on the patient's ability to produce insulin. ProTrans-Repeat is a Phase IIa clinical trial that aims to evaluate whether repeated treatment can increase or maintain the effect of ProTrans over a longer period
The Medical Products Agency has granted NextCell Pharma AB ("NextCell") permission to conduct the new study, ProTrans-Repeat. The study is a continuation of ProTrans-1 where patients with type-1 diabetes who participated in the dose escalation part will be asked to participate in ProTrans-Repeat....
Read moreRead more
2019-05-08
The Medical Products Agency grants NextCell permission to initiate the ProTrans-Repeat trial
NextCell Pharma AB ("NextCell") today received a permit from the Medical Products Agency granting permission to initiate a new clinical trial, called ProTrans-Repeat. The trials is a continuation of the ongoing ProTrans-1 trial and of great importance to the further development of ProTrans. The goal for this study is to include those patients with type 1 diabetes who participated in the dose escalation part of the ongoing ProTrans-1 study and the study purpose is to demonstrate that ProTrans also has a positive effect when using a repeated treatment approach. ProTrans-Repeat is a Phase IIa
NextCell Pharma AB ("NextCell") today received a permit from the Medical Products Agency granting permission to initiate a new clinical trial, called ProTrans-Repeat. The trials is a continuation of the ongoing ProTrans-1 trial and of great importance to the further development of ProTrans. The g...
Read moreRead more
2019-05-08
The NextCell Pharma AB board of directors proposes an Rights Issue of MSEK 24.9 and calls for an extraordinary general meeting
The Board of NextCell Pharma AB (publ) ("NextCell" or "the Company") has decided to propose an extraordinary general meeting on May 24, 2019 to decide on a rights issue of shares ("Rights Issue") totaling SEK 24.9 million. The rights issue is secured through subscription commitments and letter of intent of approximately 21 per cent and guarantee commitments of approximately 59 per cent, which corresponds to approximately 80 per cent of the total issue volume. The reason for the rights issue is to obtain working capital to expand the clinical trial program with the company's first drug
The Board of NextCell Pharma AB (publ) ("NextCell" or "the Company") has decided to propose an extraordinary general meeting on May 24, 2019 to decide on a rights issue of shares ("Rights Issue") totaling SEK 24.9 million. The rights issue is secured through subscription commitments and letter of...
Read moreRead more
2019-05-08
Discussions on a merger between NextCell AB and Idogen AB are suspended
The discussions that took place between the boards of NextCell Pharma AB ("NextCell") and Idogen AB ("Idogen") (together "The Companies"), regarding a possible merger, are suspended. Although the discussions have been characterized by pragmatism, but the boards of the companies have concluded that both companies will benefit from continuing to pursue their own activities. Even though the discussions regarding a possible merger have now been suspended, the companies choose to continue discussions on how the companies could further cooperate in the future. "We saw it as commercially logica
The discussions that took place between the boards of NextCell Pharma AB ("NextCell") and Idogen AB ("Idogen") (together "The Companies"), regarding a possible merger, are suspended. Although the discussions have been characterized by pragmatism, but the boards of the companies have concluded tha...
Read moreRead more
2019-05-06
Update regarding possible merger between NextCell Pharma AB and Idogen AB
Discussions between the boards of NextCell Pharma AB (publ) ("NextCell") and Idogen AB (publ) ("Idogen") (together "The companies") regarding a possible merger, are still ongoing. Further information will be published no later than the opening of trading on Wednesday, 08 May 2019. The companies have initiated a limited customary, legal, financial and technical/scientific due diligence. At the same time, discussions are taking place between the boards of the Companies. Additionally, the merger if implemented, will take place through an exchange offer from NextCell with consideration in
Discussions between the boards of NextCell Pharma AB (publ) ("NextCell") and Idogen AB (publ) ("Idogen") (together "The companies") regarding a possible merger, are still ongoing. Further information will be published no later than the opening of trading on Wednesday, 08 May 2019. The companies h...
Read moreRead more
2019-04-30
Half-year report
First Half (2018-09-01 till 2018-02-28) · Operating income amounted to SEK 508,7795 (391,204). · Operating result amounted to SEK -8,929,084 (-7,524,256).                         · Earnings per share* amounted to SEK -0.83 (-0.88). · Cash and bank amounted to SEK 6,886,879 (9,444,381). · Solidity** amounted to 87 (59) %. **Result per share: operating results divided by the average number of shares. Average number of shares for the first half of 2018/2019: 11,486,456 shares (8,505,425). Number of shares in NextCell as per February 28th, 11,486,456 shares (8,505,425). *
First Half (2018-09-01 till 2018-02-28) · Operating income amounted to SEK 508,7795 (391,204). · Operating result amounted to SEK -8,929,084 (-7,524,256).                         · Earnings per share* amounted to SEK -0.83 (-0.88). · Cash and bank amounted to SEK 6,886,879 (9,444,381). ...
Read moreRead more
This website uses cookies in order to improve the user experience. Read more
Preferences
DenyAccept